DCIS Clinical Trials 2024

What are the top hospitals conducting dcis research?

In the quest to better understand and treat ductal carcinoma in situ (DCIS), several hospitals have taken on the challenge with remarkable dedication. Anchorage's Providence Alaska Medical Center leads the way with three active clinical trials focused specifically on DCIS, along with a history of four completed trials since their first recorded study back in 2008. Not far behind is Northwestern University in Chicago, where researchers are currently engaged in two ongoing DCIS trials while having made significant strides through thirteen previous studies dating back to 2008.

Meanwhile, Cleveland Clinic has also made notable contributions to DCIS research, conducting two active clinical trials and building upon their three past investigations since embarking on this journey in 2015. Interestingly enough, Anchorage seems to be carving out its own niche as a hub for DCIS studies. Two local institutions—Alaska Breast Care and Surgery LLC and Alaska Women's Cancer Care— are actively involved in two concurrent clinical trials each, adding up respectively to four all-time investigations conducted by both facilities since they initiated their first-ever trial focused on DCIS exactly twelve years ago.

These dedicated hospitals demonstrate that advancements can come from unexpected places when it comes to medical breakthroughs. The shared commitment among these institutions reflects not only an eagerness to unravel the complexities of DCIS but also a testament to the power of collaborative efforts within medical communities across different locations. With every trial conducted and knowledge gained about this condition, we move one step closer towards offering improved treatment options and ultimately striving for prevention strategies that will benefit patients worldwide facing or at risk for developing ductal carcinoma in situ.

Which are the best cities for dcis clinical trials?

When it comes to DCIS (Ductal Carcinoma In Situ) clinical trials, several cities stand out as leading hubs for research and development. Anchorage, Alaska and Denver, Colorado are tied with 14 active trials each, focusing on innovative treatments like Hypofractionated Radiation Therapy, Trastuzumab, Active Monitoring, and more. Los Angeles, California follows closely behind with 12 ongoing studies exploring treatment options such as Trastuzumab and Hypofractionated Radiation Therapy. Additionally, Oakland and Sacramento in California offer promising opportunities for participation in DCIS clinical trials. These cities provide individuals diagnosed with DCIS access to cutting-edge research that can pave the way for improved care and outcomes in managing this condition.

Which are the top treatments for dcis being explored in clinical trials?

In the world of clinical trials, several promising treatments are being explored for ductal carcinoma in situ (DCIS). These include:

• Intraoperative Imaging: Currently undergoing one active trial, with a total of one DCIS trial recorded since its debut in 2022.

• Cryoablation: Showing promise, cryoablation is involved in one ongoing trial, and has been featured in two all-time DCIS trials since 2016.

• Multi-epitope HER2 Peptide Vaccine H2NVAC: Also making waves is this vaccine, currently participating in one active trial and having its first listing back in 2019.

• Hypofractionated Radiation Therapy: A notable contender on the list with a history dating back to 2011. This treatment is engaged in one active DCIS trial while accumulating three all-time trials.

What are the most recent clinical trials for dcis?

Recent clinical trials for ductal carcinoma in situ (DCIS) offer promising developments in the field of breast cancer research. One notable study focuses on intraoperative imaging, aiming to enhance surgical precision and improve outcomes for patients with DCIS. Another trial explores the potential of a multi-epitope HER2 peptide vaccine, H2NVAC, as a novel immunotherapy approach for DCIS treatment. Additionally, researchers are investigating the efficacy and safety of ruxolitinib, an innovative drug that may have therapeutic benefits specifically for individuals with DCIS. These groundbreaking trials shed light on new strategies to combat this condition and provide hope for improved management and care in the future.

What dcis clinical trials were recently completed?

Recent clinical trials for ductal carcinoma in situ (DCIS), the earliest form of breast cancer, have shown promising results. In June 2018, the National Cancer Institute successfully completed a trial investigating the potential of Bexarotene as a treatment option. Similarly, G1 Therapeutics conducted a trial testing G1T48 and concluded it in May 2018. These advancements represent significant strides towards improving our understanding and management of DCIS. The completion of these trials highlights ongoing efforts to develop innovative therapies that could potentially transform the lives of individuals diagnosed with this condition.